









Markets
/
Stocks
/
nasdaq-dnli
/

Denali Therapeutics Inc

DNLI

21.080USD

+1.060+5.29%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

3.09BMarket Cap

LossP/E TTM



Denali Therapeutics Inc

21.080

+1.060+5.29%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Denali Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Denali Therapeutics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 46 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 32.31.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Denali Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

46 / 392

Overall Ranking

153 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Denali Therapeutics Inc Highlights

StrengthsRisks

Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -7.24, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 148.33M shares, increasing 0.02% quarter-over-quarter.

Held by Paul Tudor Jones

Star Investor Paul Tudor Jones holds 56.37K shares of this stock.

Analyst Rating

Based on 18 analysts

Strong Buy

Current Rating

32.308

Target Price

+61.38%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Denali Therapeutics Inc is 5.27, ranking 375 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.27

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.57

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.97

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Denali Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Denali Therapeutics Inc is 6.48, ranking 269 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -7.24, which is -40.55% below the recent high of -4.30 and -297.25% above the recent low of -28.75.

Score

Industry at a Glance

Previous score

6.48

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 46/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Denali Therapeutics Inc is 9.00, ranking 15 out of 392 in the Biotechnology & Medical Research industry. The average price target is 32.00, with a high of 40.00 and a low of 24.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 18 analysts

Strong Buy

Current Rating

31.909

Target Price

+49.95%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Denali Therapeutics Inc

DNLI

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Denali Therapeutics Inc is 8.78, ranking 58 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 24.25 and the support level at 17.44, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.31

Change

1.47

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.026

Buy

RSI(14)

57.785

Neutral

STOCH(KDJ)(9,3,3)

34.057

Sell

ATR(14)

1.460

High Vlolatility

CCI(14)

18.496

Neutral

Williams %R

40.819

Buy

TRIX(12,20)

0.975

Sell

StochRSI(14)

25.919

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

21.380

Sell

MA10

21.293

Sell

MA20

19.921

Buy

MA50

18.594

Buy

MA100

17.107

Buy

MA200

15.816

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Denali Therapeutics Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 104.72%, representing a quarter-over-quarter decrease of 1.28%. The largest institutional shareholder is The Vanguard, holding a total of 13.02M shares, representing 8.36% of shares outstanding, with 3.16% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

11.96M

+1.47%

Baillie Gifford & Co.

Star Investors

11.59M

-3.04%

BlackRock Institutional Trust Company, N.A.

10.13M

+2.61%

Biogen Inc

7.16M

-43.89%

T. Rowe Price Investment Management, Inc.

5.64M

+73.66%

State Street Investment Management (US)

5.46M

+20.94%

Temasek Holdings Pte. Ltd.

5.36M

Fidelity Management & Research Company LLC

5.01M

-32.37%

Capital Research Global Investors

4.76M

+0.22%

T. Rowe Price Associates, Inc.

Star Investors

4.43M

-31.37%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Denali Therapeutics Inc is 5.43, ranking 47 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.03. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Denali Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.